Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status
- 30 April 2003
- journal article
- case report
- Published by Elsevier in Lung Cancer
- Vol. 40 (1) , 73-76
- https://doi.org/10.1016/s0169-5002(03)00028-x
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Tyrosine kinase inhibitors—ZD1839 (Iressa)Current Opinion in Oncology, 2001
- Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A ReviewJournal of Clinical Oncology, 2000
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)Lung Cancer, 2000